Intranasal Treatment of Central Nervous System Dysfunction in Humans

Author： Chapman Colin Frey William Craft Suzanne Danielyan Lusine Hallschmid Manfred Schiöth Helgi Benedict Christian

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.30, Iss.10, 2013-10, pp. : 2475-2484

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intranasal delivery of growth differentiation factor 5 to the central nervous system

By Hanson Leah R. Fine Jared M. Hoekman John D. Nguyen Thuhien M. Burns Rachel B. Martinez Paula M. Pohl Jens Frey William H.

Drug Delivery, Vol. 19, Iss. 3, 2012-04 ,pp. : 149-154

Informa Healthcare

Access to resources Recommend Favorite

Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook

Current Pharmaceutical Design, Vol. 19, Iss. 3, 2013-01 ,pp. : 510-526

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment

Current Pharmaceutical Design, Vol. 17, Iss. 27, 2011-09 ,pp. : 2940-2947

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacokinetic Optimisation of the Treatment of Bacterial Central Nervous System Infections

By Nau R.

Clinical Pharmacokinetics, Vol. 35, Iss. 3, 1998-09 ,pp. : 223-246

Adis International

Access to resources Recommend Favorite

Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm

By Wong Eric T

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 7, 2005-06 ,pp. : 1107-1114

Informa Healthcare

Access to resources Recommend Favorite